A broader next generation sequencing panel (Oncomine Comprehensive Assay Plus Panel) was also performed, which confirmed exon 20 insertion mutation in the HER2 gene p.(Y772_A775dup) and reported a mutation in TP53 gene p.(R248W), microsatellite stability, low tumor mutational burden and low genomic instability status. This evidence concerns the gene ERBB2 and neoplasm.